HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Alfredo Mussi Carlo Alberto Angeletti Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lucchi, M. Articles by Angeletti, C. A. Search for Related Content PubMed PubMed Citation Articles by Lucchi, M. Articles by Angeletti, C. A. Related Collections Mediastinum

Eur J Cardiothorac Surg 2001;19:566-569
© 2001 Elsevier Science NL

The multimodality treatment of thymic carcinoma

^a Cardiac and Thoracic Department, Division of Thoracic Surgery, University of Pisa, Pisa, Italy
^b Division of Pathology, University of Pisa, Pisa, Italy

Received 10 October 2000; received in revised form 7 February 2001; accepted 8 March 2001.

Corresponding author. Tel.: +39-050-995-230; fax: +39-050-577-239
e-mail: a.mussi{at}med.unipi.it

Objectives: Thymic carcinoma is a rare neoplasm more invasive and with a poorer prognosis than ordinary thymoma. Complete curative resection is sometimes not possible, but good response rates to chemotherapy are reported in literature. We report our experience with seven cases of thymic carcinoma, who took part to a multimodality treatment including neoadjuvant chemotherapy, surgery and post-operative radiotherapy in our center. Methods: Since June 1989, seven previously untreated patients were enrolled. The primary chemotherapy consisted of three courses of cisplatin (P; 75 mg/m² i.v., day 1), epidoxorubicin (E; 100 mg/m² i.v., day 1) and etoposide (VP16; 120 mg/m² i.v., days 1, 3 and 5), every 3 weeks. Surgery was performed following complete hematological recovery. After surgery, all patients underwent radiation therapy to the tumor areas, operatively marked with clips, at doses of 45 (complete resection) or 60 Gy (incomplete resection). Results: The pre-operative diagnosis of thymic carcinoma was performed in four cases by a mediastinotomy, and in the remaining cases, by an ultrasound-guided (n=2) or a computed tompography-guided (n=1) fine needle aspiration. All patients responded (one completely) to the chemotherapy regimen. Surgical resection was complete in four cases (histological examination negative in one case). Three patients are still alive and well (62–136 months from the diagnosis), two are alive with relapse at 16 and 85 months, one patient died at 86 months from another cause, and one patient died at 18 months from local relapse and lung metastases. Conclusions: A pre-operative shrinkage of the thymic carcinoma by means of neoadjuvant multi-drug chemotherapy may improve the resectability, and therefore, the survival rate. Our experience, although preliminary, is encouraging and merits additional study in a multicenter trial with a sufficient number of patients to draw definitive conclusions.

Key Words: Thymic carcinoma • Mediastinum • Neoadjuvant chemotherapy • Cisplatin • Survival

This article has been cited by other articles:

				K. Nakagawa, Y. Matsuno, H. Kunitoh, A. Maeshima, H. Asamura, and R. Tsuchiya Immunohistochemical KIT (CD117) Expression in Thymic Epithelial Tumors Chest, July 1, 2005; 128(1): 140 - 144. [Abstract] [Full Text] [PDF]

				M. Lucchi, M. C. Ambrogi, L. Duranti, F. Basolo, G. Fontanini, C. A. Angeletti, and A. Mussi Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments Ann. Thorac. Surg., June 1, 2005; 79(6): 1840 - 1844. [Abstract] [Full Text] [PDF]

				S.-i. Takeda, N. Sawabata, M. Inoue, M. Koma, H. Maeda, and H. Hirano Thymic carcinoma. Clinical institutional experience with 15 patients Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 401 - 406. [Abstract] [Full Text] [PDF]